These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 3300952)

  • 1. Successful treatment with chemotherapy and subsequent allogeneic bone marrow transplantation for myeloid blastic crisis of chronic myelogenous leukemia following advanced Hodgkin's disease.
    Punt CJ; Rozenberg-Arska M; Verdonck LF
    Cancer; 1987 Sep; 60(5):934-5. PubMed ID: 3300952
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Allogeneic bone marrow transplantation in a patient with acute myeloid leukemia secondary to Hodgkin's disease.
    de Witte T; Blacklock HA; Prentice HG; de Pauw B; Haanen C
    Cancer; 1984 Apr; 53(7):1507-8. PubMed ID: 6365303
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase II study of VP-16, intermediate-dose Ara-C and carboplatin (VAC) in advanced acute myelogenous leukemia and blastic chronic myelogenous leukemia.
    Amadori S; Picardi A; Fazi P; Testi AM; Petti MC; Montefusco E; Mandelli F
    Leukemia; 1996 May; 10(5):766-8. PubMed ID: 8656669
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Induction of molecular remission by donor peripheral blood leukocyte therapy in patients relapsing with extramedullary blastic phase chronic myeloid leukemia after allogeneic bone marrow transplantation.
    Bashey A; Shepherd S; Frankel W; Wang-Rodriguez J; Cahill T; Chamberlain M; Mason JR; Ho AD; Corringham RE
    Oncol Rep; 1998; 5(1):281-5. PubMed ID: 9458334
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Complete cytogenetic response obtained with unrelated donor lymphocyte infusion for relapse of chronic myeloid leukemia in blastic crisis after allogeneic bone marrow transplantation].
    Fujimaki K; Maruta A; Yoshida M; Yamazaki E; Matsuzaki M; Fujisawa S; Kanamori H; Ishigatsubo Y
    Rinsho Ketsueki; 2001 Mar; 42(3):204-8. PubMed ID: 11345783
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Accelerated and blastic phase of chronic myeloid leukemia.
    Dutcher JP; Wiernik PH
    Curr Treat Options Oncol; 2000 Apr; 1(1):51-62. PubMed ID: 12057061
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective single centre study of the outcome of five different therapy approaches in 48 patients with relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation.
    Elmaagacli AH; Beelen DW; Schaefer UW
    Bone Marrow Transplant; 1997 Dec; 20(12):1045-55. PubMed ID: 9466277
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Donor buffy-coat infusion and chemotherapy for leukemia in relapse after marrow transplantation.
    Bogdanić V; Aurer I; Hitrec V; Boban D; Nemet D; Zupancić-Salek S; Labar B
    Haematologica; 1995; 80(4):338-40. PubMed ID: 7590504
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term remission of T-lymphoid extramedullary blast crisis of chronic myelogenous leukemia following allogeneic bone marrow transplantation.
    Montefusco E; Mauro FR; Lo Coco F; Rondinelli B; Arcese W; Tabilio A; Monarca B; Alimena G; Mandelli F
    Haematologica; 1990; 75(4):391-3. PubMed ID: 2276682
    [TBL] [Abstract][Full Text] [Related]  

  • 10. FLANG (fludarabine + cytosine arabinoside + novantrone + G-CSF) induces partial remission in lymphoid blast transformation of Ph+chronic myelogenous leukaemia.
    Martinelli G; Testoni N; Zuffa E; Visani G; Zinzani PL; Zaccaria A; Farabegoli P; Arpinati M; Amabile M; Tura S
    Leuk Lymphoma; 1996 Jun; 22(1-2):173-6. PubMed ID: 8724545
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A case of chronic myelogenous leukemia responding to imatinib mesilate (Glivec) after relapse of blastic crisis following allogeneic bone marrow transplantation].
    Fujisawa S; Yano K; Kobayashi M
    Gan To Kagaku Ryoho; 2003 Mar; 30(3):427-30. PubMed ID: 12669406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic myelogenous leukemia in the lymphoid blastic phase: characteristics, treatment response, and prognosis.
    Derderian PM; Kantarjian HM; Talpaz M; O'Brien S; Cork A; Estey E; Pierce S; Keating M
    Am J Med; 1993 Jan; 94(1):69-74. PubMed ID: 8420302
    [TBL] [Abstract][Full Text] [Related]  

  • 13. T-cell blast crisis of chronic myelogenous leukemia manifesting as a large mediastinal tumor.
    Ye CC; Echeverri C; Anderson JE; Smith JL; Glassman A; Gulley ML; Claxton D; Craig FE
    Hum Pathol; 2002 Jul; 33(7):770-3. PubMed ID: 12196931
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Chronic myelogenous leukemia in nonlymphoid blastic phase: analysis of the results of first salvage therapy with three different treatment approaches for 162 patients.
    Sacchi S; Kantarjian HM; O'Brien S; Cortes J; Rios MB; Giles FJ; Beran M; Koller CA; Keating MJ; Talpaz M
    Cancer; 1999 Dec; 86(12):2632-41. PubMed ID: 10594858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extramedullary blast crisis in a patient with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic remission.
    O'Brien S; Witt R; Talpaz M; Kantarjian H
    Cancer; 1991 Apr; 67(7):1946-9. PubMed ID: 2004308
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of chronic myelogenous leukemia in accelerated and blastic phases with daunorubicin, high-dose cytarabine, and granulocyte-macrophage colony-stimulating factor.
    Kantarjian HM; Talpaz M; Kontoyiannis D; Gutterman J; Keating MJ; Estey EH; O'Brien S; Rios MB; Beran M; Deisseroth A
    J Clin Oncol; 1992 Mar; 10(3):398-405. PubMed ID: 1740679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of myeloid blastic crisis of chronic myelogenous leukemia.
    Preisler HD; Raza A; Higby D; Kirshner J; Woll J; Bennett J; Winton L; Weiner R; Richman C; Golomb H
    Cancer Treat Rep; 1984 Nov; 68(11):1351-5. PubMed ID: 6388833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A dose intensive regimen of cytosine arabinoside and daunorubicin for chronic myelogenous leukemia in blast crisis.
    Kouides PA; Rowe JM
    Leuk Res; 1995 Oct; 19(10):763-70. PubMed ID: 7500655
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Chemotherapy of chronic myelogenous leukemia--VP(M) regimen initiated during its chronic phase, and evaluation of MCNU in the phase of blastic crisis].
    Kitajima K; Adachi T; Takahashi I; Nakada H; Osada K; Fukuda S; Ohmoto E; Aoyama S; Yorimitsu S; Sanada H
    Gan To Kagaku Ryoho; 1989 Nov; 16(11):3573-9. PubMed ID: 2817908
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Patterns of failure following high-dose chemotherapy and autologous bone marrow transplantation with involved field radiotherapy for relapsed/refractory Hodgkin's disease.
    Mundt AJ; Sibley G; Williams S; Hallahan D; Nautiyal J; Weichselbaum RR
    Int J Radiat Oncol Biol Phys; 1995 Sep; 33(2):261-70. PubMed ID: 7673013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.